Serina Therapeutics, Inc.
SER
Rank in Stocks
#26230
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating... Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Share Price
$1.43
Last synced: 2026-11-09
Market Cap
$21.45M
Change (1 day)
3.62%
Change (1 year)
-64.95%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Serina Therapeutics, Inc. (SER)
Category
Healthcare
Operating Margin for Serina Therapeutics, Inc. (SER)
Operating Margin as of November 2026 TTM: 0.00%
According to Serina Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Serina Therapeutics, Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -30,442.86% | 30,576.00% |
| 2023 | -99.24% | -78.14% |
| 2022 | -454.07% | 745.88% |
| 2021 | -53.68% | -99.72% |
| 2020 | -19,272.22% | 2,551.69% |
| 2019 | -726.79% | -2.86% |
| 2018 | -748.21% | 24.81% |
| 2017 | -599.50% | -21.60% |
| 2016 | -764.65% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Serina Therapeutics, Inc.'s operating margin
What was Serina Therapeutics, Inc.'s operating margin in 2025?
In 2025, Serina Therapeutics, Inc.'s operating margin was 0.00%, compared with -30,442.86% in 2024.
How has Serina Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Serina Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-30,442.86%).
How does Serina Therapeutics, Inc.'s operating margin compare with similar companies?
Serina Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.